Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elvitegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elvitegravir SCHEMBL726252 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL13225651 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050769 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050765 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL2280863 | 0.94 | METTL3 (0.89) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL31577400 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL4366707 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1104875 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR | |
| SCHEMBL19829420 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | claimed |
| EP-3287130-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND PROTEASE INHIBITORS | Japan Tobacco Inc. (JP) | 2018-02-28 | — | — | EP | claimed |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2018-02-01 | — | — | US | claimed |
| US-20140364389-A1 | Combination Therapy | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | claimed |
| EP-2802315-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION | Gilead Sciences, Inc. (US) | 2014-11-19 | — | — | EP | claimed |
| US-8633219-B2 | Combination therapy | JAPAN TOBACCO INC. (JP) | 2014-01-21 | — | — | US | claimed |
| WO-2013106732-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2452682-A1 | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection | Japan Tobacco, Inc. (JP) | 2012-05-16 | — | — | EP | claimed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| EP-2332538-A1 | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents | Japan Tobacco, Inc. (JP) | 2011-06-15 | — | — | EP | claimed |
| JP-2009525265-A | — | — | 2009-07-09 | — | — | JP | claimed |
| WO-2009006199-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2009006203-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| EP-1976517-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007079260-A9 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2007-08-30 | — | — | WO | claimed |
| WO-2007079260-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1758581-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | Japan Tobacco, Inc. (JP) | 2007-03-07 | — | — | EP | claimed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | claimed |
| WO-2005112930-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | claimed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288326-A1 | Combination therapy | TYMP, TPMT, PNP | METTL3 855/4885PLA2G4A 1042/4885MAPT 1794/4885 |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | METTL3 75/4885PLA2G4A 2658/4885MAPT 3716/4885 |
| US-20140364389-A1 | Combination Therapy | TYMP, TPMT, PNP | METTL3 855/4885PLA2G4A 1042/4885MAPT 1794/4885 |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885PLA2G4A 4321/4885MAPT 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.